Cargando…
Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study
BACKGROUND: The COVID-19 pandemic required a change in outpatient care delivery models, including shifting from in-person to virtual visits, which may have impacted care of vulnerable patients. OBJECTIVE: To describe the changes in management, control, and outcomes in older people with type 2 diabet...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735737/ https://www.ncbi.nlm.nih.gov/pubmed/34993873 http://dx.doi.org/10.1007/s11606-021-07301-7 |
_version_ | 1784628305744363520 |
---|---|
author | Aubert, Carole E. Henderson, James B. Kerr, Eve A. Holleman, Rob Klamerus, Mandi L. Hofer, Timothy P. |
author_facet | Aubert, Carole E. Henderson, James B. Kerr, Eve A. Holleman, Rob Klamerus, Mandi L. Hofer, Timothy P. |
author_sort | Aubert, Carole E. |
collection | PubMed |
description | BACKGROUND: The COVID-19 pandemic required a change in outpatient care delivery models, including shifting from in-person to virtual visits, which may have impacted care of vulnerable patients. OBJECTIVE: To describe the changes in management, control, and outcomes in older people with type 2 diabetes (T2D) associated with the shift from in-person to virtual visits. DESIGN AND PARTICIPANTS: In veterans aged ≥ 65 years with T2D, we assessed the rates of visits (in person, virtual), A1c measurements, antidiabetic deintensification/intensification, ER visits and hospitalizations (for hypoglycemia, hyperglycemia, other causes), and A1c level, in March 2020 and April–November 2020 (pandemic period). We used negative binomial regression to assess change over time (reference: pre-pandemic period, July 2018 to February 2020), by baseline Charlson Comorbidity Index (CCI; > 2 vs. <= 2) and A1c level. KEY RESULTS: Among 740,602 veterans (mean age 74.2 [SD 6.6] years), there were 55% (95% CI 52–58%) fewer in-person visits, 821% (95% CI 793–856%) more virtual visits, 6% (95% CI 1–11%) fewer A1c measurements, and 14% (95% CI 10–17%) more treatment intensification during the pandemic, relative to baseline. Patients with CCI > 2 had a 14% (95% CI 12–16%) smaller relative increase in virtual visits than those with CCI <= 2. We observed a seasonality of A1c level and treatment modification, but no association of either with the pandemic. After a decrease at the beginning of the pandemic, there was a rebound in other-cause (but not hypo- and hyperglycemia-related) ER visits and hospitalizations from June to November 2020. CONCLUSION: Despite a shift to virtual visits and a decrease in A1c measurement during the pandemic, we observed no association with A1c level or short-term T2D-related outcomes, providing some reassurance about the adequacy of virtual visits. Further studies should assess the longer-term effects of shifting to virtual visits in different populations to help individualize care, improve efficiency, and maintain appropriate care while reducing overuse. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-021-07301-7. |
format | Online Article Text |
id | pubmed-8735737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-87357372022-01-07 Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study Aubert, Carole E. Henderson, James B. Kerr, Eve A. Holleman, Rob Klamerus, Mandi L. Hofer, Timothy P. J Gen Intern Med Original Research BACKGROUND: The COVID-19 pandemic required a change in outpatient care delivery models, including shifting from in-person to virtual visits, which may have impacted care of vulnerable patients. OBJECTIVE: To describe the changes in management, control, and outcomes in older people with type 2 diabetes (T2D) associated with the shift from in-person to virtual visits. DESIGN AND PARTICIPANTS: In veterans aged ≥ 65 years with T2D, we assessed the rates of visits (in person, virtual), A1c measurements, antidiabetic deintensification/intensification, ER visits and hospitalizations (for hypoglycemia, hyperglycemia, other causes), and A1c level, in March 2020 and April–November 2020 (pandemic period). We used negative binomial regression to assess change over time (reference: pre-pandemic period, July 2018 to February 2020), by baseline Charlson Comorbidity Index (CCI; > 2 vs. <= 2) and A1c level. KEY RESULTS: Among 740,602 veterans (mean age 74.2 [SD 6.6] years), there were 55% (95% CI 52–58%) fewer in-person visits, 821% (95% CI 793–856%) more virtual visits, 6% (95% CI 1–11%) fewer A1c measurements, and 14% (95% CI 10–17%) more treatment intensification during the pandemic, relative to baseline. Patients with CCI > 2 had a 14% (95% CI 12–16%) smaller relative increase in virtual visits than those with CCI <= 2. We observed a seasonality of A1c level and treatment modification, but no association of either with the pandemic. After a decrease at the beginning of the pandemic, there was a rebound in other-cause (but not hypo- and hyperglycemia-related) ER visits and hospitalizations from June to November 2020. CONCLUSION: Despite a shift to virtual visits and a decrease in A1c measurement during the pandemic, we observed no association with A1c level or short-term T2D-related outcomes, providing some reassurance about the adequacy of virtual visits. Further studies should assess the longer-term effects of shifting to virtual visits in different populations to help individualize care, improve efficiency, and maintain appropriate care while reducing overuse. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-021-07301-7. Springer International Publishing 2022-01-06 2022-03 /pmc/articles/PMC8735737/ /pubmed/34993873 http://dx.doi.org/10.1007/s11606-021-07301-7 Text en © The Author(s) under exclusive licence to Society of General Internal Medicine 2021 |
spellingShingle | Original Research Aubert, Carole E. Henderson, James B. Kerr, Eve A. Holleman, Rob Klamerus, Mandi L. Hofer, Timothy P. Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study |
title | Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study |
title_full | Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study |
title_fullStr | Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study |
title_full_unstemmed | Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study |
title_short | Type 2 Diabetes Management, Control and Outcomes During the COVID-19 Pandemic in Older US Veterans: an Observational Study |
title_sort | type 2 diabetes management, control and outcomes during the covid-19 pandemic in older us veterans: an observational study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735737/ https://www.ncbi.nlm.nih.gov/pubmed/34993873 http://dx.doi.org/10.1007/s11606-021-07301-7 |
work_keys_str_mv | AT aubertcarolee type2diabetesmanagementcontrolandoutcomesduringthecovid19pandemicinolderusveteransanobservationalstudy AT hendersonjamesb type2diabetesmanagementcontrolandoutcomesduringthecovid19pandemicinolderusveteransanobservationalstudy AT kerrevea type2diabetesmanagementcontrolandoutcomesduringthecovid19pandemicinolderusveteransanobservationalstudy AT hollemanrob type2diabetesmanagementcontrolandoutcomesduringthecovid19pandemicinolderusveteransanobservationalstudy AT klamerusmandil type2diabetesmanagementcontrolandoutcomesduringthecovid19pandemicinolderusveteransanobservationalstudy AT hofertimothyp type2diabetesmanagementcontrolandoutcomesduringthecovid19pandemicinolderusveteransanobservationalstudy |